Exchange: NASDAQ·Updated 07:30 PM EDT

BLTE News

News
all
press releases
Belite Bio, Inc. Sponsored ADR (BLTE)'s Technical Outlook is Bright After Key Golden Cross
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Zacks
More News
Belite Bio Announces NDA Submission In Japan For Tinlarebant Under Sakigake Designation
(RTTNews) - Belite Bio (BLTE) announced the submission of a New Drug Application to the Ministry of Health, Labour, and Welfare in Japan for tinlarebant in Stargardt disease type 1. Tinlarebant has been designated a SAKIGAKE pharmaceutical product for accelerated review and the N...
Nasdaq News: Markets
Why Is Belite Bio Stock Soaring Friday?
Canaccord Genuity initiates Belite Bio (BLTE) with a Buy and $303 target on FDA Priority Review for tinlarebant.read more...
Benzinga
BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
Belite Bio's tinlarebant wins FDA priority review for Stargardt Disease, with a decision expected in February 2027 after positive phase III data.
Zacks
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.read more...
Benzinga
Why Is Belite Bio Stock Gaining Monday?
Belite Bio (BLTE) stock jumps 3% on positive Phase 3 DRAGON trial data for its Stargardt disease drug candidate tinlarebant.read more...
Benzinga
Full Transcript: Belite Bio Q1 2026 Earnings Call
read more...
Benzinga
Belite Bio Enters Oversold Territory (BLTE)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me...
Nasdaq News: Markets
Belite Bio (BLTE) Q1 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
Nathan Mata Sells 1,000 Shares of Belite Bio (NASDAQ:BLTE) Stock
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Nathan Mata sold 1,000 shares of Belite Bio stock in a transaction on Tuesday, May 5th. The stock was sold at an average price...
MarketBeat

Advertisement|Remove ads.